Paramyxovirus Immunogens and Related Materials and Methods
AssigneeOhio State Innovation Foundation
InventorsJianrong Li, Yu Zhang
Life of this patent
Estimating the term…
Abstract
The present invention includes methyltransferase (MTase)-defective recombinant viruses as live vaccine candidates for human metapneumovirus (hMPV), human respiratory syncytial virus (hRSV), and human parainfluenza virus type 3 (PIV3). Here the inventors provide the technical description for generating MTase-defective paramyxoviruses useful as immunogens, as well Cas related materials and methods.
Claims27
A recombinant paramyxovirus composition comprising a nucleic acid molecule which encodes large RNA polymerase (L) protein having a defective mRNA cap MTase domain in a paramyxovirus viral genome.
A method of eliciting an immune response in a mammal comprising:
- administering to a mammal a recombinant paramyxovirus composition comprising a nucleic acid molecule which encodes large polymerase (L) protein having a defective mRNA cap MTase domain in a paramyxovirus viral genome.
A method of preparing a pharmaceutical composition for passive immunization of an individual in need of immunization comprising:
- mixing a paramyxovirus composition comprising a nucleic acid molecule which encodes large polymerase (L) protein having a defective mRNA cap MTase domain in a paramyxovirus viral genome with a suitable excipient or carrier, thereby forming a pharmaceutical composition.
Dependencies are inferred from the claim text.